ARE Patent Law Alert:
SUPREME COURT TO CLARIFY ‘ON SALE’ BAR IN HELSINN HEALTHCARE S.A. V. TEVA PHARMS. USA, INC.

On June, 25, 2018, the U.S. Supreme Court granted certiorari in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., No. 17-1229 to address the scope of the “on-sale bar” after the Leahy-Smith America Invents Act (“AIA”). Specifically, the Court will consider whether confidential prior sales of an invention trigger the on-sale bar, and qualify as […]

ARE Patent Law Alert:
USPTO GUIDANCE ON SUBJECT MATTER ELIGIBILITY OF METHOD OF TREATMENT CLAIMS

On April 13, 2018, the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) affirmed the district court’s ruling that the claims at issue in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, 887 F.3d 1117 (Fed. Cir. 2018), were patent eligible under 35 U.S.C. § 101. In a 2-1 split decision, the Court held that […]

In The Press:IPWATCHDOG Turns To Partner Charles R. Macedo For Insight on SAS Institute Decision

SAS: When the Patent Office institutes IPR it must decide patentability of all challenged claims By Gene Quinn & Renee C. Quinn  Yesterday the United States Supreme Court issued decisions in both Oil States v. Green Energyand SAS Institute v. Iancu. In Oil States the Supreme Court upheld the constitutionality of inter partes review (see here, here and here). In SAS Institute, a 5-4 majority […]